Pipeline Watch/R&D Round Up
29 January 2010
In addition to the first launch of Novartis’s antipsychotic Fanapt (iloperidone) and the first approval for the flu drug peramivir (Biocryst/Shionogi’s Rapiacta) already covered in Scrip, this week’s Pipeline Watch records the first filing by Bayer of its combined female contraceptive...
Please Login to read the full article.
29 January 2010
In addition to the first launch of Novartis’s antipsychotic Fanapt (iloperidone) and the first approval for the flu drug peramivir (Biocryst/Shionogi’s Rapiacta) already covered in Scrip, this week’s Pipeline Watch records the first filing by Bayer of its combined female contraceptive...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Supreme Court takes another stab at refining US patent law
- Latest Japanese recommendations include telaprevir and fingolimod
- Black-box warning imposed on Seattle Genetics' new lymphoma drug
- Novartis's misfortunes with Gilenya could provide a boost for other MS drug makers
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
